

# Spring 2026 Hematology Kickoff

## 2 Important Studies in Leukemia and Lymphoma Activating Soon

**S2504 pirAMID:** Richter transformation – R-CHOP w/wo pirtobrutinib

**S2506 MOZART MZL:** Marginal zone lymphoma – Identifying a new standard of care

**FRIDAY, MAY 1 • 12:30 – 1:30 PM PT • SEACLIFF AB (BAY LEVEL) & ONLINE**

### **S2504 pirAMID:** Randomized phase 3 – pirtobrutinib plus R-CHOP vs. R-CHOP alone in previously untreated Richter transformation

*Richter transformation (RT):* the progression of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) into an aggressive form of lymphoma

RT is rare (~500 cases per year in the U.S.) and highly aggressive. Prospective trial data on treatments for RT are limited, and outcomes for these patients remain poor. They need better options.

S2504 pirAMID randomizes patients with untreated RT to R-CHOP alone or R-CHOP in combination with pirtobrutinib, a BTK inhibitor that has demonstrated promising efficacy in B-cell malignancies.

#### The S2504 portion of this session will cover:

- scientific rationale for the study
- study design
- key eligibility criteria
- operational considerations
- early patient identification
- proactive patient referral



*Mazyar Shadman,  
MD, MPH  
Study Chair*



*Deborah Stephens,  
DO  
Study Co-Chair*

**S2504 is the first randomized trial in the U.S. for Richter transformation.  
Activation is imminent.**

**All NCTN and NCORP investigators and site staff are invited!**

*Also on the agenda for this kickoff session:*

**S2506 MOZART MZL:** Randomized phase 2 study in relapsed/refractory marginal zone lymphoma: mosunetuzumab alone vs. mosunetuzumab + zanubrutinib vs. mosunetuzumab + polatuzumab vedotin

# Spring 2026 Hematology Kickoff

## 2 Important Studies in Leukemia and Lymphoma Activating Soon

**S2504 pirAMID:** Richter transformation – R-CHOP w/wo pirtobrutinib

**S2506 MOZART MZL:** Marginal zone lymphoma – Identifying a new standard of care

**FRIDAY, MAY 1 • 12:30 – 1:30 PM PT • SEACLIFF AB (BAY LEVEL) & ONLINE**

**S2506 MOZART MZL** is a randomized phase 2 trial in relapsed/refractory marginal zone lymphoma comparing:

mosunetuzumab  
alone

vs.

mosunetuzumab  
+ zanubrutinib

vs.

mosunetuzumab  
+ polatuzumab vedotin

Despite marginal zone lymphoma (MZL) being the 3<sup>rd</sup> most common B-cell lymphoma, accounting for about 7,000 new diagnoses each year, there are limited prospective randomized trials to assess the safety and efficacy of new treatments in relapsed/refractory disease, and none previously through the NCTN.

The result: a standard of care for relapsed/refractory MZL remains undefined.

The S2506 (MOZART MZL) trial has emerged from a consensus effort by the NCTN groups to find a safe, efficacious, and time-limited treatment option for patients with relapsed/refractory MZL.

### The S2506 portion of this session will cover:

- study background and relevance
- trial objectives: primary, secondary, exploratory
- key eligibility criteria
- study calendar
- statistical considerations and planned analyses
- study timelines for accrual and analyses



**Boyu Hu, MD**  
Study Chair



**Sonali Smith, MD**  
Study Co-Chair

**S2506 trial activation is imminent.**

**NCTN and NCORP investigators and staff: come get your S2506 questions answered!**

*Also on the agenda for this kickoff session:*

**S2504 pirAMID:** Randomized phase 3 – pirtobrutinib plus R-CHOP vs. R-CHOP alone in previously untreated Richter transformation